After a more than decade long dormancy, the Obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade.
The only drug available for the treatment of obesity in Germany is Xenical, which is seeing a steady decrease in patient use. This is a severely underserved market, as there are simply no anti-obesity drugs available. According to GlobalData’s primary research, the percentage of patients taking Xenical is extremely low at approximately only 5% of the total patients who are overweight or obese.
Overview of Obesity including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in Germany including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in Germany from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting the Germany Obesity market.
Reasons to Buy
Understand and capitalize by identifying products that are most likely to ensure a robust return.
Stay ahead of the competition by understanding the changing competitive landscape for Obesity.
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
Make more informed business decisions from insightful and in-depth analysis of drug performance.
Obtain sales forecast for drugs from 2012-2022 in Germany.
Table of Contents
1Table of Contents1
1.1List of Tables4
1.2List of Figures6
2.1Sales for Obesity Therapy in Germany, 2012–20226
2.2What Do the Physicians Think?7
3.3Upcoming Related Reports12
4.1Etiology and Pathophysiology15
4.1.4Quality of Life17
6.2Strategic Competitor Assessment34
6.3Product Profiles: Drugs36
7Opportunity and Unmet Need46
7.2A Drug with Greater Than 10% Average Weight Loss48
7.3A Drug with Increased Safety and Tolerability50
7.4Reimbursement by Private and Public Payers51
7.5Increased Physician Education53
7.6Increased Drug-Treatment Rate55
7.8Improved Approach to Diagnosis57
8.2Promising Drugs in Clinical Development61
9.1.3Drivers and Barriers89
10.4.1Percent Drug-Treated Obesity Patients100
10.4.2Drugs Included in Each Therapeutic Class100
10.4.3Launch and Patent Expiry Dates101
10.4.4General Pricing Assumptions101
10.4.5Individual Drug Assumptions102
10.4.7Pricing of Pipeline Agents105
10.5Physicians, Specialists, and Payers Included in This Study106
10.6About the Authors109
10.6.2Therapy Director – CVMD and Infectious Disease110
10.6.3Director – Medical Devices110
10.6.4Global Head of Healthcare111
List of Tables
Table 1:Target Pathways in the Treatment of Obesity16
Table 2:Symptoms of Obesity17
Table 3: Treatment Guidelines for Obesity21
Table 4: Most Prescribed Drugs for Obesity by Class in the Global Markets, 201322
Table 5: Classification of Overweight and Obesity by BMI and Waist Circumference, and the Associated Disease Risk23
Table 6:Bariatric Treatment Attributes33
Table 7: Leading Drug Treatments for Obesity, 201334
Table 8: Marketed Obesity Treatment Devices by Type35
Table 9: Product Profile – Xenical37
Table 10: Xenical SWOT Analysis, 201339
Table 11: Product Profile – Belviq41
Table 12: Belviq SWOT Analysis, 201343
Table 13: Product Profile – Oblean45
Table 14: ObleanSWOT Analysis, 201346
Table 15: Unmet Need and Opportunity in Obesity47
Table 16: Endpoint Analysis of Clinical Trials Conducted in Obesity, 201360
Table 17: Obesity – Phase II–III Pipeline, 201361
Table 18: Comparison of Therapeutic Classes in Development for Obesity, 201363
Table 19: Obesity Treatment Pipeline Devices by Type63
Table 20: Product Profile – Contrave65
Table 21: Contrave SWOT Analysis, 201368
Table 22: Product Profile – Victoza70
Table 23: Victoza SWOT Analysis, 201374
Table 24: Product Profile – Velneperit75
Table 25: Velneperit SWOT Analysis, 201378
Table 26: Product Profile – Empatic79
Table 27: Empatic SWOT Analysis, 201382
Table 28: Sales Forecasts ($) for Obesity in Germany, 2012–202286
Table 29: Key Events Impacting Sales for Obesity in Germany, 2012–202288
Table 30: Obesity Market in Germany – Drivers and Barriers, 2012–202289
Table 31: Key Launch Dates101
Table 32: Key Patent Expiries101
List of Figures
Figure 1: Sales for Obesity in Germany by Drug Class, 2012–20227
Figure 2: Treatment Algorithm for Obesity20
Figure 3: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in Germany, 2012–202225
Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in Obesity, 2012–202262
Figure 5: Sales for Obesity in Germany by Drug Class, 2012–202287
Tel +44 (0) 20 7947 2960
Personal and transaction information are kept safe from unauthorised use.